MarketsandMarkets New release: Gene Therapy Market Price, Industry Outlook, Classification and Forecast 2024

MarketsandMarkets New release: Gene Therapy Market Price, Industry Outlook, Classification and Forecast 2024

Gene Therapy Market Overview:

The Gene Therapy Market is projected to reach USD 13.0 billion by 2024 from USD 3.8 billion in 2019, at a CAGR of 27.8% during the forecast period of 2019 to 2024. The growth of this market is majorly driven by the high prevalence of cancer and other target diseases, availability of reimbursements, and the increasing funding for gene therapy research. In addition, the launch of new products and the strong product pipeline of companies are expected to offer significant growth opportunities in this market. However, the high cost of gene therapy is expected to hamper market growth to a certain extent in the coming years.

Request For Sample:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=122857962

North America is the largest regional market for gene therapies

The global market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the market, followed by Europe. The rising prevalence of chronic diseases, high and growing healthcare expenditure, presence of advanced healthcare infrastructure, availability of reimbursements, and the presence of major market players in the region are the major factors driving the growth of the gene therapy market in North America.

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962

Market Segmentation:

The non-viral vectors segment accounted for the largest share of the gene therapy market, by vector, in 2018

The gene therapy market, by vector, has been segmented into viral and non-viral vectors. Non-viral vectors accounted for the largest share of the market in 2018. This is mainly attributed to the high market penetration of oligonucleotide-based non-viral vector gene therapies.

The demand for gene therapies for the treatment of cancer is expected to grow at a high rate

Based on indication, the gene therapy market is segmented into neurological diseases, cancer, hepatological diseases, Duchenne muscular dystrophy, and other indications. The neurological diseases segment accounted for the largest share of the market in 2018. However, the cancer segment is estimated to grow at the highest CAGR during the forecast period owing to the increasing incidence of cancer and the rising demand for CAR T-cell therapies.

Get Detailed Information:

https://www.marketsandmarkets.com/Market-Reports/gene-therapy-market-122857962.html

Key Players:

The prominent players operating in the gene therapy market include Biogen (US), Novartis AG (Switzerland), Gilead Sciences, Inc. (US), Spark Therapeutics, Inc. (US), MolMed S.p.A. (Italy), Orchard Therapeutics plc. (UK), SIBIONO (China), Shanghai Sunway Biotech Co., Ltd. (China), bluebird bio, Inc. (US), Human Stem Cells Institute (Russia), AnGes, Inc. (Japan), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics (US), Jazz Pharmaceuticals, Inc. (Ireland), Akcea Therapeutics (US), and Dynavax Technologies (US).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model — GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly Singh

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

More Information:

https://www.marketsandmarkets.com/PressReleases/gene-therapy.asp

https://www.prnewswire.com/news-releases/gene-therapy-market-worth-13-0-billion-by-2024---exclusive-report-by-marketsandmarkets-300989478.html

https://www.marketsandmarketsblog.com/gene-therapy-market-high-incidence-of-cancer-other-targeted-diseases-to-drive-market-growth.html

https://www.whatech.com/markets-research/medical/719876-examine-the-future-of-gene-therapy-market